PPT-THERAPEUTIC HSV-2 VACCINE (
Author : phoebe-click | Published Date : 2016-06-30
GEN003 RESULTS IN DURABLE REDUCTION IN GENITAL LESIONS AT 1 YEAR Phase 12a Clinical Trial GEN003001 Anna Wald MD MPH University of Washington annawalduwashingtonedu
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "THERAPEUTIC HSV-2 VACCINE (" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
THERAPEUTIC HSV-2 VACCINE (: Transcript
GEN003 RESULTS IN DURABLE REDUCTION IN GENITAL LESIONS AT 1 YEAR Phase 12a Clinical Trial GEN003001 Anna Wald MD MPH University of Washington annawalduwashingtonedu Conflict of interest. John S. Burr, MD, FCCP. Illinois Heart and Lung Associates. Advocate Medical Group. <?xml version="1.0"?><AllQuestions />. <?xml version="1.0"?><AllAnswers />. <?xml version="1.0"?><Settings><answerBulletFormat>Numeric</answerBulletFormat><answerNowAutoInsert>No</answerNowAutoInsert><answerNowStyle>Explosion</answerNowStyle><answerNowText>Answer Now</answerNowText><chartColors>Use PowerPoint Color Scheme</chartColors><chartType>Vertical</chartType><correctAnswerIndicator>Checkmark</correctAnswerIndicator><countdownAutoInsert>No</countdownAutoInsert><countdownSeconds>10</countdownSeconds><countdownSound>TicToc.wav</countdownSound><countdownStyle>Box</countdownStyle><gridAutoInsert>No</gridAutoInsert><gridFillStyle>Answered</gridFillStyle><gridFillColor>255,255,0</gridFillColor><gridOpacity>100%</gridOpacity><gridTextStyle>Keypad #</gridTextStyle><inputSource>Response Devices</inputSource><multipleResponseDivisor># of Responses</multipleResponseDivisor><participantsLeaderBoard>5</participantsLeaderBoard><percentageDecimalPlaces>0</percentageDecimalPlaces><responseCounterAutoInsert>No</responseCounterAutoInsert><responseCounterStyle>Oval</responseCounterStyle><responseCounterDisplayValue># of Votes Received</responseCounterDisplayValue><insertObjectUsingColor>Blue</insertObjectUsingColor><showResults>Yes</showResults><teamColors>User Defined</teamColors><teamIdentificationType>None</teamIdentificationType><teamScoringType>Voting pads only</teamScoringType><teamScoringDecimalPlaces>1</teamScoringDecimalPlaces><teamIdentificationItem></teamIdentificationItem><teamsLeaderBoard>5</teamsLeaderBoard><teamName1></teamName1><teamName2></teamName2><teamName3></teamName3><teamName4></teamName4><teamName5></teamName5><teamName6></teamName6><teamName7></teamName7><teamName8></teamName8><teamName9></teamName9><teamName10></teamName10><showControlBar>Slides with Get Feedback Objects</showControlBar><defaultCorrectPointValue>100</defaultCorrectPointValue><defaultIncorrectPointValue>0</defaultIncorrectPointValue><chartColor1>187,224,227</chartColor1><chartColor2>51,51,153</chartColor2><chartColor3>0,153,153</chartColor3><chartColor4>153,204,0</chartColor4><chartColor5>128,128,128</chartColor5><chartColor6>0,0,0</chartColor6><chartColor7>0,102,204</chartColor7><chartColor8>204,204,255</chartColor8><chartColor9>255,0,0</chartColor9><chartColor10>255,255,0</chartColor10><teamColor1>187,224,227</teamColor1><teamColor2>51,51,153</teamColor2><teamColor3>0,153,153</teamColor3><teamColor4>153,204,0</teamColor4><teamColor5>128,128,128</teamColor5><teamColor6>0,0,0</teamColor6><teamColor7>0,102,204</teamColor7><teamColor8>204,204,255</teamColor8><teamColor9>255,0,0</teamColor9><teamColor10>255,255,0</teamColor10><displayAnswerImagesDuringVote>Yes</displayAnswerImagesDuringVote><displayAnswerImagesWithResponses>Yes</displayAnswerImagesWithResponses><displayAnswerTextDuringVote>Yes</displayAnswerTextDuringVote><displayAnswerTextWithResponses>Yes</displayAnswerTextWithResponses><questionSlideID></questionSlideID><controlBarState>Expanded</controlBarState><isGridColorKnownColor>True</isGridColorKnownColor><gridColorName>Yellow</gridColorName><AutoRec></AutoRec><AutoRecTimeIntrvl></AutoRecTimeIntrvl><chartVotesView>Percentage</chartVotesView><chartLabelsColor>0,0,0</chartLabelsColor><isChartLabelColorKnownColor>True</isChartLabelColorKnownColor><chartLabelColorName>Black</chartLabelColorName><chartXAxisLabelType>Answer Bullets</chartXAxisLabelType></Settings>. Outshouting the Noise. Lchezem@aol.com. Entry to Criminal Court. A broad term that refers to judicial approaches that address the offender’s behavior as a problem requiring non-traditional sanctions and/or social services in addition to traditional sanctions.. in the Workplace. Nicholas . Mosca, M.Div.. nick@nickmosca.com. @. revelinrev. nickmosca.com. . Who is this guy?. Theologian: . Inspirational . Speaker . & Writer. Educator. Neurotic . New Yorker . Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI 1 2 Summary of the AIDS epidemic 2016 Necessity to go beyond cART Since the introduction of ART 20 years ago, Describe . myaesthenia. gravis & its management. Explain . Organophosphorous. poisoning & treatment. C. holinergic agonists. By . Dr.Sajid. . Hussain. Cholinergic agonist- . Classification. phase . 1 clinical trial in HIV-1 infected . patients. Escaich Sonia, . COO . BIOSANTECH . SA.. Tat is a virulence factor of HIV. Transactivator. of transcription (Tat) of HIV-1 is essential for the viral . ESCNJ Board PresentationNarrated by Dr Deborah Eisenberg PT DPT MSClinical Services DirectorFebruary 23 2018INTRODUCTIONEvidence ased tractice provided by hTs and tTsManagement presence at each siteEx ESCNJ Board PresentationNarrated by Dr Deborah Eisenberg PT DPT MSClinical Services DirectorFebruary 23 2018INTRODUCTIONEvidence ased tractice provided by hTs and tTsManagement presence at each siteEx temperature between and 8C 36 and 46F DTaP Tdap Td DT type bHibPolio IPVMeningococcal ACWYRotavirusShingrix ZosterMMRVVaricellatemperature between -50 and -15C -58 and 5FreezerRefrigeratorManage vacc across the product lifespan. TRUSTED to ensure the SAFETY and EFFICACY of all therapeutic products. FLEXIBLE and RISK APPROPRIATE with enabling legislation framework to ensure therapeutic products are ACCESSIBLE . Mark Hatherill. South African Tuberculosis Vaccine Initiative (SATVI). University of Cape Town, South Africa. 2. The case for a therapeutic vaccine for DR-TB. What could a therapeutic vaccine do?. What could we do with a therapeutic vaccine?. Lchezem@aol.com. Entry to Criminal Court. A broad term that refers to judicial approaches that address the offender’s behavior as a problem requiring non-traditional sanctions and/or social services in addition to traditional sanctions.. M. uted. Unmuted. Please ensure that your line is not generating background noise. We are recording this webinar; you will be placed on mute by default. Please remain on mute if you are not speaking to maintain the quality of the recording. Aging. What is Therapeutic Recreation? . Therapeutic recreation often allows clients to learn to live to the fullest recognizing their abilities. The therapy promotes physicality and assists older adults to explore, discover, or .
Download Document
Here is the link to download the presentation.
"THERAPEUTIC HSV-2 VACCINE ("The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents